P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB
Bibliographic record
Abstract
Topic: 16. Myeloproliferative neoplasms - Clinical Background: In addition to splenomegaly and constitutional symptoms, anemia is a high medical need in patients with myelofibrosis (MF). Although anemia in patients with MF is commonly managed with red blood cell (RBC) transfusions, their use can be detrimental to survival and quality of life as well as a burden on the healthcare system. A recently developed clinical prognostic model supports the negative prognostic impact of requiring RBC transfusions during the initial 6 months of ruxolitinib (RUX) treatment on survival (Maffioli et al, 2022). Momelotinib (MMB) is a small-molecule inhibitor of activin receptor type 1 (ACVR1), Janus kinase 1 (JAK1), and JAK2, with clinical activity against anemia, constitutional symptoms, and splenomegaly. Prespecified anemia endpoints in MMB phase 3 studies have prioritized achievement of a strict transfusion independence response (TI-R), defined as no transfusions for ≥12 weeks immediately before the end of week 24, with all hemoglobin (Hb) levels ≥8 g/dL. However, this binominal response/nonresponse endpoint does not fully characterize the changes in transfusion burden in patients with MF. Aims: In a phase 2 translational biology study of MMB in transfusion-dependent (TD) patients with MF, 34% of patients (14/41) achieved a TI-R by week 24 (Oh et al, 2020). However, the transfusion burden and treatment effect on overall transfusion burden of the entire study population has not been reported. Novel transfusion burden analyses presented here examine transfusion frequency over time in TD patients with MF treated with MMB. Methods: All RBC units transfused and Hb levels associated with transfusions were collected during the 24-week study period and for the 56 days before initiation of MMB on study. Eligible patients were to be TD at baseline, defined as ≥4 RBC units in the 56 days before start of MMB study treatment, which for this analysis was defined as a prestudy average of ≥2 units per 28 days. Time-dependent transfusion burden was quantified by number of RBC units administered, in a tabular display of baseline- and treatment-period intensity. Patients were grouped jointly based on the baseline- and treatment-period intensity of RBC units per 28 days into ordinal bins: exactly zero units, >0 to 1 unit, >1 to 2 units, >2 to 3 units, >3 to 4 units, and >4 units. Results: At baseline, 98% of patients (40/41) enrolled were TD and 88% (36/41) were JAK inhibitor naive, with a mean Hb of 8.3 g/dL and a mean platelet count of 181×103/µL. The mean RBC transfusion requirement was 3.2 units per 28 days before MMB treatment, with a range of 1.5 to 6.0 units per 28 days; 98% of patients (40/41) had transfusion needs of ≥2.0 units per 28 days. The mean transfusion requirement after MMB initiation was reduced from 3.2 to 1.7 units per 28 days (range, 0-6 units per 28 days), with 85% of patients (35/41) achieving a numeric reduction in transfusions. Using the ordinal bins, 90% of patients (37/41) showed improved (26/41) or stable (11/41) transfusion intensity with MMB treatment (Figure). Nine patients (22%) became transfusion free for the entire treatment period, while transfusion requirements modestly increased in 4 patients (10%). Summary/Conclusion: These data demonstrate that nearly all RBC TD patients treated with MMB (90%) experience a decline or stabilization of transfusion requirements, which further supports the differentiated activity of MMB against ACVR1, JAK1, and JAK2, resulting in decreased plasma hepcidin, improved iron homeostasis, and increased erythropoiesis, in addition to symptomatic and splenic benefits. FigureKeywords: Anemia, Transfusion, Myelofibrosis
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".